Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of “Buy” by Analysts

Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) have been assigned an average rating of “Buy” from the ten brokerages that are covering the stock, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy rating and three have given a strong buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $17.56.

Several equities research analysts have recently weighed in on TRVI shares. HC Wainwright reiterated a “buy” rating and set a $12.50 target price on shares of Trevi Therapeutics in a research note on Wednesday, March 19th. Needham & Company LLC reaffirmed a “buy” rating and set a $24.00 price objective on shares of Trevi Therapeutics in a research report on Tuesday, April 8th. Oppenheimer boosted their target price on Trevi Therapeutics from $12.00 to $20.00 and gave the company an “outperform” rating in a report on Tuesday, March 11th. Raymond James raised Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and increased their price target for the stock from $9.00 to $29.00 in a report on Monday, March 10th. Finally, D. Boral Capital reissued a “buy” rating and issued a $21.00 price objective on shares of Trevi Therapeutics in a research note on Wednesday, March 19th.

Trevi Therapeutics Stock Performance

Shares of TRVI stock opened at $6.10 on Friday. The stock’s 50-day moving average is $5.42 and its two-hundred day moving average is $4.12. Trevi Therapeutics has a 1 year low of $2.30 and a 1 year high of $7.39. The firm has a market cap of $589.76 million, a price-to-earnings ratio of -13.86 and a beta of 0.41.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings results on Tuesday, March 18th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.01. As a group, research analysts predict that Trevi Therapeutics will post -0.49 EPS for the current year.

Insiders Place Their Bets

In other news, insider Farrell Simon sold 81,313 shares of Trevi Therapeutics stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $6.75, for a total transaction of $548,862.75. Following the completion of the sale, the insider now directly owns 76,900 shares in the company, valued at approximately $519,075. This trade represents a 51.39 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jennifer L. Good sold 5,263 shares of the company’s stock in a transaction that occurred on Friday, March 21st. The stock was sold at an average price of $6.58, for a total value of $34,630.54. Following the completion of the sale, the chief executive officer now owns 213,313 shares in the company, valued at approximately $1,403,599.54. This represents a 2.41 % decrease in their position. The disclosure for this sale can be found here. Insiders own 24.37% of the company’s stock.

Institutional Trading of Trevi Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Summit Investment Advisors Inc. raised its holdings in Trevi Therapeutics by 84.2% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company’s stock valued at $26,000 after acquiring an additional 2,894 shares during the last quarter. BNP Paribas Financial Markets increased its stake in Trevi Therapeutics by 130.9% during the third quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock worth $40,000 after acquiring an additional 6,764 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Trevi Therapeutics in the 4th quarter worth about $49,000. Squarepoint Ops LLC acquired a new position in shares of Trevi Therapeutics in the 4th quarter valued at about $58,000. Finally, Two Sigma Advisers LP purchased a new stake in shares of Trevi Therapeutics during the 4th quarter worth about $66,000. Hedge funds and other institutional investors own 95.76% of the company’s stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.